US › Healthcare

Latigo Biotherapeutics, Inc. Common Stock (LTGO)

US · Healthcare · Biotechnology

$23.93+3.77%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-25.8M

EPS

$-27.59

EPS estimate

$-0.66

EPS came in at -27.59 against a street estimate of -0.66 — a miss of 4080.3%.

Key statistics

Market cap

$1.53B

Forward P/E

0.0

P/B

0.00

Book value

$-279.37

EPS (TTM)

$-1.88

52-week high

$25.93

52-week low

$17.22

50-day MA

$21.56

200-day MA

$21.56

Analyst view

with an average price target of $52.25.

Shareholding

Insiders

4.98%

Institutions

75.30%

Recent filings & reports

Document	Date
Quarterly report · Q2 2026 LATIGO BIOTHERAPEUTICS, INC. — Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash Position: $55.0 million as of June 30, 2026 (down from $69.4 millio	2026-09-03
Results announced · Q3 2026 LATIGO BIOTHERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • IPO Proceeds: Raised gross proceeds of $397.4 million from upsized initi	2026-09-03
Charter / bylaws change · Q3 2026 LATIGO BIOTHERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • IPO Completion Date: August 10, 2026 • Shares Offered: 19,200,000 shares of common sto	2026-08-10

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Latigo Biotherapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.